LEVIN ARTHUR A 4

What Happened
Arthur A. Levin, a director of Stoke Therapeutics (STOK), reported an open-market sale of 605 shares on March 13, 2026. The shares were sold at $36.80 per share for a total transaction value of $22,264. This was a sale (not a purchase); sales by insiders can be routine and do not by themselves indicate a change in company outlook.

Key Details

• Transaction date: 2026-03-13; Type: Sale (Code S)
• Price per share: $36.80; Shares sold: 605; Total value: $22,264
• Shares owned after transaction: Not disclosed in this filing
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2025
• Filing timeliness: Report filed on 2026-03-17 (within the Form 4 reporting window)

Context
The sale was executed under a pre-established 10b5-1 trading plan, which typically schedules trades in advance and can limit the informational value of the trade as a signal. For retail investors, purchases generally carry more weight as signals of insider conviction; single, pre-planned sales like this are commonly routine liquidity events.